Twenty-year experience with the St Jude Medical mechanical valve prosthesis John S Ikonomidis, MD, PhD, John M Kratz, MD, Arthur J Crumbley, MD, Martha.

Slides:

Advertisements

Similar presentations

W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

Advertisements

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Twenty-Five Year Experience With the St

Manuel J. Antunes, MD, PhD, DSc

Clinical event rates with the On-X bileaflet mechanical heart valve: A multicenter experience with follow-up to 12 years John B. Chambers, MD, FRCP,

Clinical experience with the carbomedics valve: Early results with a new bileaflet mechanical prosthesis J.Francisco Nistal, MD, Aquilino Hurlé, MD,

Influence of the On-X mechanical prosthesis on intermediate-term major thromboembolism and hemorrhage: A prospective multicenter study Vincent Chan,

“Lead from the front”: Participative leadership

Prospective randomized comparison of CarboMedics and St

Bigger valve size is not always better

Ultrasound, endoscopy, and the recurrent nerve

A 10-Year Experience With the Carbomedics Cardiac Prosthesis

Anticoagulation in Children With Mechanical Valve Prostheses

Eleven-Year Single-Center Experience with the ATS Open Pivot Bileaflet Heart Valve Doan Baykut, MD, Leticia Grize, PhD, Christian Schindler, PhD, Angelika.

Ground glass opacity of the lung: The veil that needs lifting

W. R. Eric Jamieson, MD, Guy J. Fradet, MD, James G

Accounting for outcomes: Lies, damned lies, and statistics

Form ever follows function

Early degeneration of the St Jude Medical Trifecta bioprosthetic aortic valve: A problem of the leaflets or of the stent? Giuseppe Santarpino, MD, Steffen.

Scott A. Hittinger, MD, Tom P. Theruvath, MD, PhD, John S

Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: An 8-year retrospective.

Surgeons, valve repair in severely unbalanced atrioventricular septal defect, and the emperor's new clothes David M. Overman, MD The Journal of Thoracic.

Bigger The Journal of Thoracic and Cardiovascular Surgery

Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement Ole Lund, MD, PhD, Martin Bland,

Use of Recombinant Activated Factor VII Concentrate to Control Postoperative Hemorrhage in Complex Cardiovascular Surgery Lyndsey J. Bowman, Walter E.

The lord of the rings Antonio Miceli, MD, PhD

The variability of the mitral valve anatomy and terminology

Are older patients with mechanical heart valves at increased risk?

Does the degree of preoperative mitral regurgitation predict survival or the need for mitral valve repair or replacement in patients with anomalous origin.

Long-term evaluation of biological versus mechanical prosthesis use at reoperative aortic valve replacement Vincent Chan, MD, MPH, B-Khanh Lam, MD, MPH,

Quality of mitral valve surgery at the United States Department of Veterans Affairs Juan A. Crestanello, MD The Journal of Thoracic and Cardiovascular.

W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

Innovation and science: The future of valve design

It's not “just a shunt” but sometimes it should be…

Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 years Charles A. Yankah, MD, PhD, Miralem Pasic, MD,

Military surgeons just want to have fun

A first start for lung transplantation?

Transcatheter aortic valve replacement and surgical aortic valve replacement: Both excellent therapies J. James Edelman, MBBS(Hons), PhD, Vinod H. Thourani,

Up to 8-year follow-up of valve replacement with CarboMedics valve

Fifteen years of experience with ATS mechanical heart valve prostheses

Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: Clinical and economic outcomes Walter.

Results of valve replacement with omniscience mechanical prostheses

Robert W. Emery, MD, Christopher C. Krogh, Kit V. Arom, MD, PhD, Ann M

Surgery for aortic and mitral valve disease in the United States: A trend of change in surgical practice between 1998 and 2005 Scott D. Barnett, PhD,

Vivek Rao, MD, PhD, Carolyn M. David, BN

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

The Journal of Thoracic and Cardiovascular Surgery

Instrumental variable methods in clinical research

Bradley G. Leshnower, MD, Robert A. Guyton, MD, Richard J

Thirty-year experience with a bileaflet mechanical valve prosthesis

St Jude Medical Regent valve

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Arnt E Fiane, MD, Odd R Geiran, MD, PhD, Jan L Svennevig, MD, PhD

Process is helpful, but the procurement problem persists

First nights, the adrenal axis, and steroids

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

Tissue valve, nitinol stent, or storage solution

The future of cardiac surgery training: A survival guide

Vinay Badhwar, MD, John S. Ikonomidis, MD, PhD, Jeffrey P. Jacobs, MD

“The more things change…”: The challenges ahead

John M. Stulak, MD, Joseph A. Dearani, MD, Harold M

Managing conflicts of interest

First in line for robotic surgery: Would you want to know?

Clinical event rates with the On-X bileaflet mechanical heart valve: A multicenter experience with follow-up to 12 years John B. Chambers, MD, FRCP,

Chordal replacement with polytetrafluoroethylene sutures for mitral valve repair: A 25- year experience Tirone E. David, MD, Susan Armstrong, MSc, Joan.

Melanie D. Everitt, MD, Nelangi Pinto, MD, John A. Hawkins, MD, Max B

Which biologic valve should we select for the 45- to 65-year-old age group requiring aortic valve replacement? F. Dagenais, MD, P. Cartier, MD, P. Voisine,

Haider J. Warraich, MD, Robert W. Sewell, MD, Robert M. Sade, MD

Thanos Sioris, MD, Tirone E

Presentation transcript:

Twenty-year experience with the St Jude Medical mechanical valve prosthesis John S Ikonomidis, MD, PhD, John M Kratz, MD, Arthur J Crumbley, MD, Martha R Stroud, MS, Scott M Bradley, MD, Robert M Sade, MD, Fred A Crawford, MD The Journal of Thoracic and Cardiovascular Surgery Volume 126, Issue 6, Pages 2022-2031 (December 2003) DOI: 10.1016/j.jtcvs.2003.07.005

Figure 1 Actuarial survival after AVR and MVR. The Journal of Thoracic and Cardiovascular Surgery 2003 126, 2022-2031DOI: (10.1016/j.jtcvs.2003.07.005)

Figure 2 Actuarial and “actual” freedom from reoperation after AVR and MVR. The Journal of Thoracic and Cardiovascular Surgery 2003 126, 2022-2031DOI: (10.1016/j.jtcvs.2003.07.005)

Figure 3 Actuarial and “actual” freedom from thromboembolic events after AVR and MVR. The Journal of Thoracic and Cardiovascular Surgery 2003 126, 2022-2031DOI: (10.1016/j.jtcvs.2003.07.005)

Figure 4 Actuarial and “actual” freedom from bleeding events after AVR and MVR. The Journal of Thoracic and Cardiovascular Surgery 2003 126, 2022-2031DOI: (10.1016/j.jtcvs.2003.07.005)

Figure 5 Actuarial and “actual” freedom from valve-related morbidity or mortality after AVR and MVR. The Journal of Thoracic and Cardiovascular Surgery 2003 126, 2022-2031DOI: (10.1016/j.jtcvs.2003.07.005)